# Jadenu (deferasirox) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/deferasirox

> The FDA approved Jadenu (deferasirox), sponsored by NOVARTIS AG (NVS), on May 18, 2017.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Jadenu (deferasirox) |
| Codes |  |
| Sponsor | NOVARTIS AG (NVS) https://sec-api.dev/companies/nvs/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### May 18, 2017: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA207968 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20170518, review_priority STANDARD; sponsor_name NOVARTIS; product JADENU SPRINKLE (DEFERASIROX)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207968%22

### July 23, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA206910 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20200723, review_priority STANDARD; sponsor_name NOVARTIS PHARMS CORP; product JADENU (DEFERASIROX)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA206910%22
- openFDA Drugs@FDA: "NDA021882 SUPPL-33 (Efficacy): submission_status AP, submission_status_date 20200723, review_priority STANDARD; sponsor_name NOVARTIS; product EXJADE (DEFERASIROX)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA021882%22
- openFDA Drugs@FDA: "NDA207968 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20200723, review_priority STANDARD; sponsor_name NOVARTIS; product JADENU SPRINKLE (DEFERASIROX)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207968%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/deferasirox.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Jadenu (deferasirox) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/deferasirox

```bibtex
@misc{secapidev_pdufa_deferasirox_20261116,
  title        = {Jadenu (deferasirox) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/deferasirox}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_deferasirox_20261116","title":"Jadenu (deferasirox) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/deferasirox","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
